Why the study?
As many as 75% of patients with PCOS are estimated to be unidentified in clinical practice.
Does a polygenic and phenotypic risk score improve the prediction of polycystic ovary syndrome compared to a null model in a multi-ancestry EHR cohort?
Observational (n=124,852)
Does a polygenic and phenotypic risk score improve the prediction of polycystic ovary syndrome compared to a null model in a multi-ancestry EHR cohort?
Answers are grounded in this paper and cite their sources.
A combined polygenic and phenotypic risk score significantly improves the detection of PCOS across different ancestries and identifies shared biology with metabolic and endocrine outcomes.
CONTEXT: As many as 75% of patients with polycystic ovary syndrome (PCOS) are estimated to be unidentified in clinical practice. OBJECTIVE: Utilizing polygenic risk prediction, we aim to identify the phenome-wide comorbidity patterns characteristic of PCOS to improve accurate diagnosis and preventive treatment. DESIGN, PATIENTS, AND METHODS: Leveraging the electronic health records (EHRs) of 124 852 individuals, we developed a PCOS risk prediction algorithm by combining polygenic risk scores (PRS) with PCOS component phenotypes into a polygenic and phenotypic risk score (PPRS). We evaluated its predictive capability across different ancestries and perform a PRS-based phenome-wide association study (PheWAS) to assess the phenomic expression of the heightened risk of PCOS. RESULTS: The integrated polygenic prediction improved the average performance (pseudo-R2) for PCOS detection by 0.228 (61.5-fold), 0.224 (58.8-fold), 0.211 (57.0-fold) over the null model across European, African, and multi-ancestry participants respectively. The subsequent PRS-powered PheWAS identified a high level of shared biology between PCOS and a range of metabolic and endocrine outcomes, especially with obesity and diabetes: "morbid obesity", "type 2 diabetes", "hypercholesterolemia", "disorders of lipid metabolism", "hypertension", and "sleep apnea" reaching phenome-wide significance. CONCLUSIONS: Our study has expanded the methodological utility of PRS in patient stratification and risk prediction, especially in a multifactorial condition like PCOS, across different genetic origins. By utilizing the individual genome-phenome data available from the EHR, our approach also demonstrates that polygenic prediction by PRS can provide valuable opportunities to discover the pleiotropic phenomic network associated with PCOS pathogenesis.
No takes yet. Share an insight, caveat, or question.
Joo et al. (2020) conducted an observational in Polycystic ovary syndrome (PCOS) (n=124,852). Polygenic and phenotypic risk score (PPRS) vs. Null model was evaluated on PCOS detection performance (pseudo-R2).
Synapse has enriched 10 related papers. Consider them for comparative context: